Therapeutic targeting of fibrotic epithelial-mesenchymal transition–an outstanding challenge

A. Fintha, Ákos Gasparics, L. Rosivall, Attila Sebe

Research output: Contribution to journalArticle

2 Citations (Scopus)


Back in 1995, a landmark paper was published, which shaped the fibrosis literature for many years to come. During the characterization of a fibroblast-specific marker (FSP1) in the kidneys, an observation was made, which gave rise to the hypothesis that “fibroblasts in some cases arise from the local conversion of epithelium.” In the following years, epithelial-mesenchymal transition was in the spotlight of fibrosis research, especially in the kidney. However, the hypothesis came under scrutiny following some discouraging findings from lineage tracing experiments and clinical observations. In this review, we provide a timely overview of the current position of the epithelial-mesenchymal transition hypothesis in the context of fibrosis (with a certain focus on renal fibrosis) and highlight some of the potential hurdles and pitfalls preventing therapeutic breakthroughs targeting fibrotic epithelial-mesenchymal transition.

Original languageEnglish
Article number388
JournalFrontiers in Pharmacology
Issue numberMAR
Publication statusPublished - Jan 1 2019



  • Chronic injury
  • Epithelial to mesenchymal transition
  • Fibrosis
  • Myofibroblast
  • Repair

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this